Dicerna Pharmaceuticals (DRNA) is a clinical stage biotechnology company specializing in RNAi-based medicines. Its most advanced candidate is nedosiran for primary hyperoxaluria, a rare genetic disease. But it also has entered into collaboration agreements with Boehringer Ingelheim, Alexion (ALXN), Lilly (LLY), Roche (RHHBY), and Novo Nordisk (NVO). This indicates a great deal of industry confidence in the Dicerna GalXC platform's capabilities. Dicerna has a strong cash position allowing it to pursue its commercialization goals. At the same time, Dicerna's market capitalization is well below that of other